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Explanted D grafts exhibited near-normal features, whereas 
the presence of calcification, inflammatory infiltrates, and 
disarray of elastic lamellae occurred in some DC grafts. In 
the unaltered regions of AVCs from both groups, almost 
complete re-endothelialization was observed for both valve 
cusps and aorta walls. In addition, side-by-side repopula-
tion by recipient’s fibroblasts, myofibroblasts, and smooth 
muscle cells was paralleled by ongoing tissue remodeling, 
as revealed by the ultrastructural identification of typical 
canals of collagen fibrillogenesis and elastogenesis-related 
features. Incipient neo-vascularization and re-innervation 
of medial and adventitial tunicae of grafted aortic walls 
were also detected for both D and DC groups. Cryopreser-
vation did not affect post-implantation AVC hemodynamic 
behavior and was topically propensive to cell repopulation 
and tissue renewal, although graft deterioration including 
calcification was present in several areas. Thus, these pre-
liminary data provide essential information on feasibility of 
decellularization and cryopreservation coupling in the per-
spective of treatment optimization and subsequent clinical 
Abstract Decellularized porcine aortic valve conduits 
(AVCs) implanted in a Vietnamese Pig (VP) experimen-
tal animal model were matched against decellularized and 
then cryopreserved AVCs to assess the effect of cryopreser-
vation on graft hemodynamic performance and propensity 
to in vivo repopulation by host’s cells. VPs (n = 12) under-
went right ventricular outflow tract substitution using AVC 
allografts and were studied for 15-month follow-up. VPs 
were randomized into two groups, receiving AVCs treated 
with decellularization alone (D; n = 6) or decellularization/
cryopreservation (DC; n = 6), respectively. Serial echo-
cardiography was carried out to follow up hemodynamic 
function. All explanted AVCs were processed for light and 
electron microscopy. No signs of dilatation, progressive 
stenosis, regurgitation, and macroscopic calcification were 
echocardiographically observed in both D and DC groups. 
M. Gallo and A. Bonetti contributed equally to this work.
F. Ortolani, L. Iop and G. Gerosa are equally responsible for the 
concept and design of the study.
 * Michele Gallo 
 michelegallo@hotmail.co.uk
 Gino Gerosa 
 gino.gerosa@unipd.it
1 Division of Cardiac Surgery, Department of Cardiac, 
Thoracic and Vascular Sciences, University of Padua,  
Via Giustiniani 2, 35128 Padua, Italy
2 Department of Experimental and Clinical Medicine, 
University of Udine, Udine, Italy
3 Department of Animal Medicine, Productions and Health, 
University of Padua, Legnaro, Italy
4 Department of Biomedical Sciences, University of Padua, 
Padua, Italy
5 Tissue Bank of Veneto Region, Treviso Regional Hospital, 
Treviso, Italy
6 Department of Cardiac, Thoracic and Vascular Sciences, 
Biostatistics, Epidemiology and Public Health Unit, 
University of Padua, Padua, Italy
7 Department of Cardiothoracic Surgery, Royal Children’s 
Hospital, Murdoch Children’s Research Institute, University 
of Melbourne, Melbourne, Australia
8 Cardiovascular Regenerative Medicine, Venetian Institute 
of Molecular Medicine (VIMM), Biomedical Campus Pietro 
d’Abano, Padua, Italy
 Heart Vessels
1 3
trials using similarly treated human allografts as innovative 
heart valve substitutes.
Keywords Bioengineering · Heart valve · 
Decellularization · Cryopreservation · Echocardiography · 
Preclinical model
Introduction
Valvular heart disease represents a major public health 
problem responsible for significant morbidity and mortality 
worldwide. Valve replacement surgery is the leading thera-
peutic option, with approximately 300,000 valve prostheses 
required per year, worldwide [1]. The European Homo-
graft Bank has recently reported a total of 4516 allograft 
valve implantations during the last 20 years for the repair 
or reconstruction of diseased ventricular outflow and inflow 
tracts (1391 aortic, 2620 pulmonary, and 48 mitral) [2]. 
Nevertheless, available allograft valves in cryopreserved 
stocks are insufficient to meet clinical demand. Long-term 
failure rate of allogeneic valve conduits is similar to that 
described for glutaraldehyde-treated xenografts [3]. Clini-
cal studies have demonstrated that allograft failure could be 
at least partly the result of cellular and humoral immune 
responses to human leukocyte antigens (HLA), which are 
present in implanted allografts [4]. Although good preser-
vation of the extracellular matrix (ECM) has been reported 
for cryopreserved allografts [5, 6], damage to collagen and/
or elastin was shown to occur during the cryopreservation/
thawing process [7, 8] as result of crystal ice formation 
and/or proteinase release by non-viable cells. These injured 
tissue elements may exacerbate the calcification process 
[9], which is primed by hydroxyapatite nucleation on dying 
valve interstitial cells and their debris in both in vivo [10] 
and in vitro [11] experimental models.
Previous in vivo investigation indicated that decellular-
ized pulmonary valves implanted in the ovine right ven-
tricular outflow tract (RVOT) exhibited a lower incidence 
of cusp and wall calcification than cryopreserved native 
pulmonary valves [12]. Furthermore, the hemodynamic 
performance of the decellularized pulmonary valves was 
comparable to the cryopreserved counterparts, exhibiting 
significantly lower pressure gradients compared with cur-
rent glutaraldehyde-treated bioprostheses (Medtronic, Inc, 
Freestyle Bioprosthesis; Medtronic, Minneapolis, MN) 
[13]. To avoid the problems caused by valvular tissue treat-
ment with glutaraldehyde, physical crosslinking procedures 
were employed such as dye mediated photo-oxidation [14].
The combination of osmotic shock, cell membrane 
emulsification with Triton X-100/Sodium Cholate (TRI-
COL), and nucleic acid digestion with aspecific endonu-
cleases has proven to be a very promising decellularization 
procedure. In fact, it provides a suitable preservation of the 
texture of native valve interstitium and hemodynamic per-
formance [15–17], with concurrent removal of the xenoan-
tigen galactose-α-1,3-galactose (alpha-gal) [18]. In addi-
tion, TRICOL-treated porcine aortic valve conduits (AVCs) 
were shown to exhibit physiological performance for up to 
15 months after implantation in Vietnamese Pigs (VPs) as 
well as permissivity to repopulation by recipient’s cells and 
tissue remodeling capability, as revealed by ex vivo mor-
phological analyses [19, 20].
Currently, the creation of innovative bioengineered heart 
valves represents a promising research field. Coupling 
decellularization and cryopreservation procedures would 
be an ideal strategy for an off-the-shelf, self-regenerating, 
functional valve prostheses, allowing both long-term stor-
age and ready availability.
In the perspective of future clinical trials, this prelimi-
nary study focuses on the impact of combined TRICOL 
decellularization and subsequent standard cryopreservation 
on AVC allografts using the validated VP animal model, 
at least showing propensity to cell repopulation and tissue 
renewal.
Materials and methods
Isolation, decellularization, and cryopreservation 
of aortic allografts
Porcine hearts (n = 12) were harvested from young com-
mon breeding piglets (3–4 months old) at a local abattoir 
and stored in sterile cold saline solution with a full comple-
ment of antimicrobial agents (penicillin 100 U/mL, strepto-
mycin 100 mg/mL, and amphotericin B 250 µg/mL) until 
further processing. AVCs were isolated by aseptic exci-
sion performed according to an established tissue harvest 
procedure [19], with a warm ischemic time less than 1 h. 
TRICOL decellularization of 12 AVCs was carried out as 
previously described [15]. Briefly, aortic homografts were 
treated with a combination of osmotic shock and a Triton 
X100 plus sodium cholate (TRICOL) detergent solution. 
An endonuclease treatment (Benzonase, Merck, Darm-
stadt, Germany) was applied to remove remaining nuclear 
fragments. Before being frozen, decellularized AVCs were 
immersed in a cryopreservant solution composed of RPMI 
1640 with 0.3 g/L of l-Glutamine (Sigma-Aldrich, Saint 
Louis, MO, USA) and containing 10 % dimethylsulfoxide 
(Sigma-Aldrich, Saint Louis, MO, USA) and 10 % of 20 % 
human albumin (Kedrion Biopharma, Inc., Fort Lee, NJ, 
USA) as cryoprotective agents. AVCs were sterilely main-
tained in low-temperature-resistant polypropylene package 
and cryocooled in a liquid nitrogen computerised freezer 
(ICECUBE 1860, Icemachinedepot, Fayetteville, NC, 
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USA) with controlled temperature lowering (−1 °C/min 
until −140 °C). Subsequently, storage was performed in 
the accredited “Tissue Bank of Veneto Region” (Regional 
Authorization number 3948, 15 December 2000) under 
controlled conditions between −140 and −185 °C in a liq-
uid nitrogen vapor tank.
VP chronic implant model
The Italian Ministry of Health authorized the University 
of Padua to use VPs for the experimental purposes of this 
study (27/08 C16 project), conforming to D. Lgs. n.116 
(art. 12; January 27, 1992). All animal experiments and 
surgical procedures were performed in compliance with 
ISO 10993-1, ISO 10993-2, and UNI EN ISO 5840 stand-
ards. VPs (n = 12) were randomized into group D (n = 6), 
consisting in VPs subjected to RVOT substitution with 
allogeneic TRICOL-decellularized AVCs, and group DC 
(n = 6), consisting in VPs subjected to RVOT substitution 
with TRICOL-decellularized and cryopreserved AVCs. 
AVCs from both groups were implanted in 12-month-old 
VPs (54.3 ± 2.5 and 69.0 ± 3.7 kg for females and males, 
respectively) using beating heart cardiopulmonary bypass. 
Surgical procedure and postoperative management were 
performed as previously described [19–21].
Echocardiography
Echocardiographic evaluation [22] was performed under 
general anesthesia preoperatively at 15 days and 1, 3, 6, 
12, 15 months after surgery. Transthoracic 2D echocar-
diographic analyses were carried out using an ultrasound 
device (Zonare™ Zone Ultra, Mountain View, USA) 
equipped with a phased array sector transducer (1–4 MHz). 
Transesophageal 3D live echocardiography was performed 
using a iE33 xMATRIX (Philips, Eindhoven, The Nether-
lands). Valve function was assessed evaluating pulmonary 
stenosis (peak transvalvular gradient; PTG), pulmonary 
regurgitation (absent = 0, trivial = 1st degree, mild = 2nd 
degree, moderate = 3rd degree, and severe = 4th degree), 
and right ventricular function (secondary tricuspid 
regurgitation).
Explantation of AVC conduits
AVCs were explanted under general anesthesia 15 months 
after implantation, and animals were euthanized with Tanax 
[20]. Both D and DC AVCs were excised under aseptic 
conditions, examined macroscopically, and documented 
photographically.
Histology
Samples of explanted AVCs were fixed with phosphate-
buffered 4 % paraformaldehyde and cut to obtain specimens 
comprising the valve cusp and a segment of the adjacent 
aortic wall as well as the anastomosis between the donor’s 
aortic wall and the recipient’s pulmonary one. Specimens 
were then paraffin-embedded, cut into 4-μm-thick sec-
tions, and stained with: (1) hematoxylin and eosin (H&E) 
(2) Masson’s trichrome, (3) Weigert’s method for elastic 
fiber selective staining, (4) alcian blue dissolved in sodium 
acetate buffer containing 0.05 M magnesium chloride for 
total glycosaminoglycan (GAG) visualization, and (5) von 
Kossa method for selective visualization of calcium-bind-
ing sites. Observations and photographic recordings were 
made using a Zeiss AxioImager photomicroscope (Carl 
Zeiss, Oberkochen, Germany).
Immunohistochemistry
Histological sections were deparaffinized and pre-treated 
with a phosphate-buffered saline (PBS) solution containing 
0.1 % Triton X-100 for 10 min and a PBS solution contain-
ing 3 % hydrogen peroxide for 5 min. Sections were then 
incubated with PBS solutions containing (1) 3 % normal 
donkey serum for 40 min, (2) 1:1500 rabbit anti-PGP 9.5 
polyclonal antibody (UltraClone Limited, Rossiters Farm 
House Wellow, Isle of Wight, England) or 1:100 rabbit 
anti-von Willebrand factor (Dako, Glostrup, Denmark) for 
90 min at r.t. in a humidified chamber, and (3) 1:600 don-
key anti-rabbit peroxidase-conjugated secondary antibody 
(Jackson ImmunoResearch Laboratories, West Grove, PA) 
for 30 min. Peroxidase activity was revealed by incuba-
tion with diaminobenzidine chromogen (BioGenex, San 
Ramon, CA) for 3 min. Finally, immunoreacted sections 
were faintly counterstained with haematoxylin, dehydrated 
in graded ethanols, cleared with xylene, and mounted 
with Eukitt®. As negative controls, primary antibody was 
replaced with normal donkey serum. Observations and pho-
tographic recordings were performed as above.
Transmission electron microscopy
Samples of explanted AVCs were fixed with phosphate-
buffered 2.5 % glutaraldehyde and 2.5 % formaldehyde 
and cut to obtain valve cusp and aortic wall specimens 
which were: (1) post-fixed with 2 % osmium tetraoxide 
(Agar Scientific, Essex, England), (2) dehydrated in graded 
ethanols, and (3) embedded in Araldite/Epon (Agar Scien-
tific, Essex, England). Ultrathin sections were collected on 
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formvar-coated 2 × 1-mm-slot copper grids and contrasted 
with uranyl acetate and lead citrate. Observations and 
photographic records were made using a Philips CM12/
STEM electron microscope (Philips, Eindhoven, The 
Netherlands).
Statistical analysis
All data are reported as mean and standard deviation. Dif-
ferences between groups were analyzed using Mann–Whit-
ney U test. Intra-group differences during follow-up were 
evaluated using Wilcoxon signed-rank test. A p value of 
0.05 was considered to be statistically significant [23]. For 
statistical analyses, SAS 9.1 statistical software package 
(SAS Institute Inc., Cary, NC, USA) was used.
Results
Operative results
Both D and DC AVCs showed adequate mechanical prop-
erties during surgical implantation and weaning from 
extracorporeal circulation. Early surgical complications, 
such as excessive bleeding with cardiac tamponade, graft 
displacement, and sternal dehiscence, did not occur, dem-
onstrating that VPs are eligible for the surgical technique. 
One animal in D group showed a progressive valvular ste-
nosis with severe right ventricular failure due to massive 
endocarditis and thrombosis in the graft, so it was excluded 
from the study. In DC group, one animal died due to ven-
tricular fibrillation after surgery and necropsy revealed 
native endocarditis in the tricuspid valve. Iatrogenic com-
plications due to AVC damage during surgical anastomosis 
affected another animal. These two distinct animals were 
also excluded from the study.
Echocardiographic assessment
AVCs from both D and DC groups showed no echocar-
diographic structural deterioration, evident signs of cusp 
thickening or reduction of cusp mobility or microbial veg-
etations during the 15 months of follow-up. During follow-
up, PTGs in D and DC groups 15 days after surgery were 
27.8 ± 5.8 and 36 ± 16.6 mmHg, respectively. The gra-
dients remained stable over time (p = 0.1224), with PTGs 
at month 15 measuring 31.8 ± 13.4 and 20.5 ± 4.1 mmHg, 
respectively, without significant difference between the two 
groups (p = 0.2509). However, these values were signifi-
cantly higher (p < 0.001) than the preoperative recordings 
(2.66 ± 0.9 and 2.75 ± 1.2 mmHg for D and DC group, 
respectively) (Fig. 1a). A significant increase (trivial\mild 
regurgitation) in pulmonary insufficiency (p = 0.0015) was 
noted in both D and DC groups comparing preoperative 
data (trivial regurgitation) with those recorded 15 months 
after graft implantation (trivial\mild regurgitation), 
although these values remained unchanged over the post-
operative time (p = 0.0880), with no significant difference 
between the two groups (p = 0.8561) (Fig. 1b). For both 
groups, the right ventricular function was preserved and 
there was no significant secondary tricuspid insufficiency 
(Fig. 1c). Hyperechogenic areas were assessed near the 
proximal and distal sutures, as expected.
Macroscopic examination of explanted allografts
Macroscopically, no recognizable signs of tissue altera-
tions (graft rupture, cusp thickening, fibrin deposits, gross 
calcification, and microbial vegetation) were found for D 
allografts (Fig. 2), except for the presence of two punc-
tate opacified regions affecting one valve cusp in one of 
the five grafts. Conversely, DC allografts exhibited appar-
ently near-normal regions coexisting with others showing 
alterations such as opacization, stiffening, and thicken-
ing of valve cusps and/or aorta walls. These injuries were 
heterogeneously sized and randomly distributed, involving 
either valve cusps or aortic walls, as noted for two grafts, 
and both valve cusps and aortic walls, as noted for the other 
two grafts.
Light microscopy
Histologically, both positive features and negative ones 
were observed, with worse patterns being mainly shown 
by DC samples. Since the aim of this study is to provide 
improvement in processing of cadaver-derived aortic valve 
substitutes, only pictures of DC samples will be illustrated.
In general, unaltered regions in both D and DC allo-
graft cusps were characterized by a native-like distribution 
of collagen fibers, elastic lamellae, and GAG component 
(Fig. 3a, c, g, i). Cusp cell repopulation was also apparent.
Namely, the valve cusps appeared to be covered by 
a monolayer of flattened cells (Fig. 3a, c, g, i), showing 
immunopositivity for endothelial cell marker von Wille-
brand factor (Fig. 3e).
Moreover, a side-by-side distribution of irregularly or 
spindle-shaped cells was observed throughout the cusp 
interstitium (Fig. 3a, c, g, i). Monolayered flattened cells 
were found to cover also the aortic wall luminal surfaces 
(Fig. 3b, d), exhibiting immunopositivity for endothelial 
cell marker von Willebrand factor (Fig. 3f). Host cells were 
also found to repopulate tunica media and, at greater extent, 
tunica adventitia (Fig. 3b, d, h), in which ECM components 
showed an apparently unaltered array of collagen (Fig. 3b, 
h) and elastin components (Fig. 3d). In addition, evident re-
vascularization occurred in the outer tunica media and the 
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Fig. 1  Echocardiographic assessment of D (n = 5) allografts com-
pared with DC (n = 4) counterparts. Peak transvalvular gradients 
were significantly higher than the preoperative values, although they 
remained stable over time. No significant differences were appreci-
able between the two groups (a). Pulmonary regurgitation was trivial\
mild after implantation without worsening during the follow-up in 
both D and DC groups (b). Secondary tricuspid regurgitation was 
absent/trivial in both groups (c) (absent = 0; trivial = 1st degree; 
mild = 2nd degree; moderate = 3rd degree; severe = 4th degree). 
Data are reported as mean value (histograms) and standard deviation 
(bold line)
Fig. 2  Macroscopic features of 
explanted allografts. Opacifica-
tion of aortic wall was observed 
after explantation in DC group, 
while cusps were translucent 
and surface did not present 
macroscopic alterations (a). 
Aorta wall of D group showed 
a normal appearance without 
fibrin deposits (b)
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Fig. 3  Histological and 
immunohistochemical analyses 
of DC allografts. AVC cusps 
showing re-endothelialization 
of both their aspects (a, c, g, i, 
arrowheads) by cells showing 
immunopositivity for von Wille-
brand factor (e) as well as side-
by-side cell repopulation (a, 
c, g, i), flanked by native-like 
distribution of collagen fibers 
(a, g), elastin lamellae (c), and 
glycosaminoglycan component 
(i). AVC walls showing focal 
re-endothelialization of luminal 
surfaces (arrowheads in b, d) 
by intimal cells immunopositive 
for von Willebrand factor (f), 
besides repopulation of tunica 
media (b, d), containing appar-
ently unaltered elastic laminae 
(d), and tunica adventitia (h, j), 
containing both newly formed 
blood vessels (h, arrows) and 
PGP-9.5-immunopositive nerve 
fibers (j, arrows). Bar 0.5 mm 
(a–d, g–i); 120 μm (e, f); 
0.4 mm (j)
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entire tunica adventitia (Fig. 3h), the latter also demonstrat-
ing incipient re-innervation, as revealed by immunopositiv-
ity of thin nerve fibers for PGP 9.5 neural marker (Fig. 3j). 
However, important tissue alterations, such as presence of 
fibrin deposits, inflammatory infiltrates, calcific foci, scarce 
GAG component, and fragmented elastin fibers, were also 
encountered in both valve cusps and aorta walls, with these 
adverse outcomes occurring more frequently in the DC 
group than the D group.
AVC ultrastructure
Ultrastructural analysis of unaltered AVC samples from 
both D and DC groups better revealed the presence of 
ongoing tissue regeneration. Namely, endothelial-like flat 
cells were found to cover both aspects of grafted valve 
cusps, being (1) arranged as monolayers, (2) intercon-
nected by immature tight junctions, and (3) underlined by 
thin basal laminae (Fig. 4a). In the valve cusp interstitium, 
several repopulating cells exhibited fibroblast features 
(Fig. 4b), while other cells were rich in intracytoplasmatic 
myofilaments and interconnected by immature cell junc-
tions, resembling myofibroblasts, the irregularly shaped 
ones (Fig. 4c), and smooth muscle cells, the oblong ones 
(Fig. 4d). In addition, clear features of ongoing ECM neo-
synthesis were apparent, such as (1) presence of collagen 
fibrils having smaller diameters than in mature fibrils in 
adult valve cusps (Fig. 4c–f), (2) abundance of the char-
acteristic canal-shaped cell indentations involved in col-
lagen fibrillogenesis (Fig. 4e), and (3) prominent juxta-
cellular distribution of small immature elastin fibers, i.e., 
elaunin fibers associated with abundant fibrillin microfibrils 
(Fig. 4f). Similar cell repopulation patterns and associ-
ated ECM neo-synthesis were apparent in the aortic walls 
(Fig. 5a–e). In addition, newly formed intramural blood 
vessels were encountered (Fig. 5f), with luminal surfaces 
covered by joined endothelium-like cells underlined by 
continuous basal laminae, some of which exhibited multi-
ple arrangement as often occurring during angiogenic pro-
cesses (Fig. 5g).
Discussion
The ideal bioengineered AVC would be a fully compatible 
graft, with the potential to grow with the patient, remodel, 
and self-regenerate. From our previous experience [19–21], 
spontaneous tissue-guided regeneration of acellular scaf-
folds from native heart valves proved to be an appealing 
technique for a straight-forward and functional clinical 
application. Previous studies utilize as animal model the 
juvenile sheep and more recently also the elderly sheep 
[24–26]. In this context, the allogeneic VP model has been 
shown to be a suitable experimental system for in vivo, 
long-term validation of valve prostheses, since it produces 
coagulation and inflammatory responses, as in transplanted 
patients. In the present study, the same VP animal model 
was used to match the performance of TRICOL-decellular-
ized valve allografts against that of TRICOL-decellularized 
valve allografts subsequentially subjected to cryopreser-
vation. Since cryopreservation is mandatory to preserve 
human allogeneic valves for use in valve replacement, 
this study may be conceived as an anticipation of a possi-
ble human clinical trial. Both D and DC aortic allografts 
used in this study were obtained from breeding piglets and 
implanted in the pulmonary position of VPs to anticipate 
the potential outcomes deriving from their clinical use as 
RVOT substitutes. Decellularized valvular scaffolds were 
found to undergo progressive cell repopulation, acting as 
functional substitutes at least for 15 months, without show-
ing any dilatation or failure. Although a limitation of this 
study was the relatively small number of enrolled animals, 
statistical analysis indicated that both D and DC grafts did 
not show significant time-related increasing in PTGs after 
implantation. These results are in line with other reports 
regarding biological valvular scaffolds, for which the gra-
dients remained constant during the entire period of follow-
up [24–27]. However, PTGs were significantly higher than 
the preoperative gradients and the short-term nature of this 
event precludes the genesis of a pathological stenosis. It is 
likely that PTG modification may depend on mechanical 
factors, such as anatomy of aortic root, patient-prosthesis 
mismatch, or pressure recovery, and biological factors, 
such as infection, coagulation, inflammation, cell repopula-
tion, and ECM synthesis [28, 29]. Of interest, an in vitro 
study demonstrated that TRICOL-treated valves showed 
lower gradients than in controls (non-decellularized, native 
valves) [17]. Conversely, right ventricular function was 
preserved, as indicated by absence of significant second-
ary tricuspid insufficiency for both groups. Both D and DC 
grafts also showed trivial/mild regurgitation after surgery, 
which persisted for entire follow-up, without increasing. 
These results correlate with our previous in vitro stud-
ies reporting a prolonged phase of cusp coaptation during 
diastole concerning TRICOL-treated valve prostheses [17]. 
The adopted decellularization treatment, therefore, is likely 
to make the cusp more flexible, facilitating the trivial/
mild regurgitation observed in vivo. However, comparing 
this parameter with that related to autografts repositioned 
in orthotopic position, no significant differences were 
observed [19]. Conversely, decellularizing treatments using 
trypsin/EDTA were seen to be more aggressive and induce 
structural damage, causing moderate valvular regurgitation 
soon after implantation [30, 31].
Since cryopreservation is employed to allow ready 
availability and long-term storage of valve prostheses, the 
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present study tested the in vivo performance of TRICOL-
decellularized and then cryopreserved valve allografts. 
Notably, the obtained results revealed that cryopreserva-
tion does not affect the functional performance of DC 
allografts. Moreover, despite the possibility of cryopreser-
vation-dependent graft alterations [7–9], AVCs from DC 
group were found to be permissive to cell repopulation, as 
revealed by the identification of recipient’s cells colonizing 
Fig. 4  Ultrastructure of aortic valve cusps from DC allografts. AVC 
cusps lined by surfacing endothelial-like cells (a En = endothelium) 
with a thin basal lamina (arrow); a fibroblast-like cell populating a 
native-like interstitium (b); two myofibroblast-like cells (c) intercon-
nected by cell junctions (circles); native-like smooth muscle cells (d) 
filled with actin myofilaments (asterisk); presence of characteristic 
native-like canals of collagen fibrillogenesis (arrows in e) and neo-
synthesis of elastin fibers (f E = elaunin fibers). Bar 1 μm (a, c, d, f); 
5 μm (b); 0.5 μm (e)
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Fig. 5  Ultrastructure of aortic valve walls from DC allografts. AVC 
walls showing endothelial-like cells covering the aorta luminal sur-
face (a En = endothelium; f = sub-endothelial fibroblast; E = elas-
tin fibers). Tunica media showing native-like smooth muscle cells 
(b) interconnected by cell junctions (circles) and rich in actin myo-
filaments (asterisk); myofibroblast-like cells involved in elastin fiber 
neo-synthesis (c E = elaunin fibers); fibroblast-like cells (d) showing 
canals of collagen fibril neo-synthesis (arrowhead). Media extracel-
lular matrix (e) exhibiting native-like arrayed collagen fibrils, periodi-
cally interconnected by orthogonal small proteoglycans (C + PGs), 
and mature elastin fibers (e) with the presence of regenerated blood 
vessels (f) containing mature erythrocytes (Er). Blood vessel (g) lined 
by interconnected endothelial-like cells (arrows; L = lumen) under-
lined by a multiple basal lamina. Bar 2.5 μm (a, f); 1 μm (b, c, e, g); 
0.5 μm (d)
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the aortic graft, as well as ECM neo-synthesis, demon-
strated by the presence of (1) typical canals of collagen 
fibrillogenesis, (2) abundant small-diameter collagen fibrils, 
and (3) elaunin and immature elastic fibers, as observed for 
D grafts. Of note, such tissue regeneration features were 
accompanied by re-vascularization and re-innervation of 
the tunica adventitia and the outer tunica media of grafted 
aorta walls, key events for valve tissue renewal and func-
tionality. On the other hand, re-endothelialization of valve 
cusps and aorta wall luminal surfaces was seen to be more 
complete for grafted AVCs from D group. It is likely that 
cryopreservation affects the integrity of native endothelium 
basal lamina, compromising its preservation after TRICOL 
treatment alone [19] and exposing DC grafts to fibrin depo-
sition and/or infiltration by inflammatory cells.
Morphologically, DC allografts exhibited calcification 
spots in both valve cusps and aorta walls. Betchel et al. 
reported a high frequency of calcification (26 %) in Syner-
Graft® allografts (Cryolife), as revealed by CT scan post-
operatively after 10-month follow-up. However, no signifi-
cant change in valvular function was echocardiographically 
detected [32]. The Cryolife use as cryoprotectant solution a 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
10 % v/v fetal bovine serum and 10 % v/v dimethyl sulfox-
ide [6]. A survey conducted in 24 international heart valve 
banks show numerous differences on heart valve processing 
techniques used in term of sterile culture media, cryopro-
tectant reagent, antibiotic/antimycotic cocktail, controlled 
rate freezing for cryopreservation, and storage of allografts 
at ultralow temperatures [33]. These findings suggest that 
ECM damage induced by cryopreservation and thawing is 
mainly responsible for calcification, since decellularization 
treatment preserves allografts from cell death-associated tis-
sue mineralization, which commonly affects native human 
homografts [4, 9–11]. To avoid cryopreservation, Cebotari 
et al. reported the use of fresh decellularized valves that are 
stored up to 3 weeks at +4 °C before implantation. How-
ever, this technique requires that patients await graft avail-
ability and are admitted to the hospital at short notice [34]. 
Indeed, the impact of cryopreservation on the scaffold 
texture is paramount for the long-term durability of decel-
lularized heart valves. Schenke-Layland reported that col-
lagen and elastin architecture was specifically disrupted 
in response to the cryopreservation/thaw cycling [8] and 
proposed a novel heart valve preservation method which 
ensures ECM preservation avoiding ice formation and tis-
sue-glass cracking [35]. On the contrary, Gerson et al. indi-
cated that conventional cryopreservation of human heart 
valve allografts does not affect collagen and elastin struc-
tural integrity [6]. Narine et al. investigated the effects of 
cryopreservation on the structural and biochemical proper-
ties of decellularized porcine aortic valves, which was found 
to not significantly alter collagen and uronic acid content of 
aortic cusp matrices. However, histological and ultrastruc-
tural analyses showed extensive disruption to affect collagen 
fibrils as well as inter-fibrillar small proteoglycans [36].
It is well known that the extent of freezing/thawing dam-
age depends upon the amount of free water in the ECM and 
its propensity to crystallization. The major role of cryopro-
tectants, when used at high concentrations, seems to be the 
induction of vitrification, i.e., extracellular glass formation. 
Compared to traditional cryopreservation, vitrification pro-
motes non-crystalline or amorphous water solidification 
rather than crystallization, limiting the amount of ice crys-
tal formation [33]. Currently, a promising cryoprotectant 
is VS83, consisting in a combination of 4.65 M dimethyl-
sulfoxide, 4.65 M formamide, and 3.3 M 1,2-propanediol 
[37].
On the whole, the present results indicate that cryo-
preservation mitigates some of the favorable outcomes pro-
vided by TRICOL decellularization treatment. However, it 
is worth noting that neither allograft hemodynamic perfor-
mance, as revealed by the functional comparison, nor their 
propensity to appropriate cell repopulation and associated 
tissue renewal, as shown histologically and ultrastructur-
ally, were compromised.
Future investigations will combine TRICOL decellu-
larizing treatment and ice-free cryopreservation [34] for 
in vivo evaluation of hemodynamic performance, propen-
sity to cell repopulation, and tissue remodeling capability 
of bioengineered valve substitutes in long-term follow-up.
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